134 related articles for article (PubMed ID: 3104047)
1. Effects of intra-arterial prostaglandin E1 in patients with peripheral arterial occlusive disease.
Creutzig A; Creutzig H; Alexander K
Eur J Clin Invest; 1986 Dec; 16(6):480-5. PubMed ID: 3104047
[TBL] [Abstract][Full Text] [Related]
2. Skin oxygen pressure histograms in patients with peripheral arterial occlusive disease during intraarterial and intravenous prostaglandin E1 infusions of different dosages and their prognostic value.
Creutzig A; Arnold A; Caspary L; Thum J; Alexander K
Angiology; 1995 May; 46(5):357-67. PubMed ID: 7741319
[TBL] [Abstract][Full Text] [Related]
3. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
Weiss T; Eckstein H; Weiss C; Diehm C
Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of action of prostaglandin E1 in therapy of peripheral arterial occlusive diseases].
Weiss T
Vasa; 2003 Nov; 32(4):187-92. PubMed ID: 14694766
[TBL] [Abstract][Full Text] [Related]
6. Transcutaneous PO2 and laser Doppler flowmetry in patients with arterial occlusive disease receiving intraarterial infusions of PGE1 or nucleotide phosphates.
Caspary L; Creutzig A; Alexander K
Prog Clin Biol Res; 1987; 242():433-8. PubMed ID: 2959965
[No Abstract] [Full Text] [Related]
7. [Effect of intra-arterial and intravenous PGE1 infusions on transcutaneous oxygen pressure in patients with critical ischemia of the extremities].
Weiss T; Griesshaber J; Rogatti W; Kistner O; Hsu E; Jansen T; Diehm C
Vasa Suppl; 1991; 33():341-2. PubMed ID: 1788749
[TBL] [Abstract][Full Text] [Related]
8. [Hemodynamic effects of intermittent intra-arterial infusion treatment with prostaglandin E1 in peripheral arterial occlusive disease].
Ranke C; Creutzig A; Alexander K
Med Klin (Munich); 1991 Jul; 86(7):349-52, 382. PubMed ID: 1921896
[TBL] [Abstract][Full Text] [Related]
9. Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Peskar BA; Hesse WH; Rogatti W; Diehm C; Rudofsky G; Schweer H; Seyberth HW
Prostaglandins; 1991 Mar; 41(3):225-8. PubMed ID: 1852896
[TBL] [Abstract][Full Text] [Related]
10. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
Weiss T; Fischer D; Hausmann D; Weiss C
Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced alterations in muscle tissue oxygen pressure in patients with arterial occlusive disease.
Creutzig A; Alexander K
Int J Microcirc Clin Exp; 1985; 4(2):173-81. PubMed ID: 2412983
[TBL] [Abstract][Full Text] [Related]
12. Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease.
Hirai M; Nakayama R
Br J Surg; 1986 Jan; 73(1):20-3. PubMed ID: 3947867
[TBL] [Abstract][Full Text] [Related]
13. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
Herold A; Bruch HP; Hörl M; Düsel W
Prog Clin Biol Res; 1987; 242():439-44. PubMed ID: 2959966
[TBL] [Abstract][Full Text] [Related]
14. Effect of prostaglandin E1 upon collateral vessels in peripheral occlusive arterial disease.
Rudofsky G; Gerngross U
Prog Clin Biol Res; 1989; 301():407-9. PubMed ID: 2798455
[No Abstract] [Full Text] [Related]
15. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
16. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
Heidrich H
Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
[TBL] [Abstract][Full Text] [Related]
17. Skin surface oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlusive disease.
Creutzig A; Caspary L; Alexander K
Klin Wochenschr; 1990 Feb; 68(4):207-12. PubMed ID: 2314008
[TBL] [Abstract][Full Text] [Related]
18. [Transcutaneous pO2 and laser Doppler flux in increasing doses of intraarterial and intravenously administered prostaglandin E1].
Creutzig A; Caspary L; Ranke C; Kiessling D; Wilkens J; Frölich J; Alexander K
Vasa; 1987; 16(2):114-8. PubMed ID: 2955602
[No Abstract] [Full Text] [Related]
19. Influence of prostaglandin E1 on muscular tissue-PO2 in patients with diabetic gangrene.
Heinrich R; Krawzak HW; Strosche H
Adv Exp Med Biol; 1989; 248():699-704. PubMed ID: 2506745
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
Balzer K; Rogatti W; Rüttgerodt K
Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
